This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.
Bayer’s Nubeqa (darolutamide) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment for patients with metastatic hormone-sensitive prostate cancer ... The drug is currently approved as
The Janssen Pharmaceutical Companies of Johnson &Johnson and AbbVie’s Imbruvica (ibrutinib) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment ... Imbruvica is already used in the NHS
Astellas Pharma’s experimental monoclonal antibody zolbetuximab has shown promising results when used as part of a combination treatment in certain gastric cancer patients, according to detailed phase 3 results recently ... The late-stage SPOTLIGHT
The dMMR cohort of 225 evaluable patients saw a 70% reduced risk with the combination therapy compared to chemotherapy alone after a median follow-up of 12 months. ... Keytruda already has two approved indications for certain patients with endometrial
ABBV-95 is a combination of foscarbidopa and foslevodopa, the prodrugs for the commonly used carbidopa and levodopa (CD/LD). ... a new treatment that can enable better symptom control through the continuous 24-hour administration of medication".
Currently, the standard treatment for untreated DLBCL is the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP). ... More than 60 countries have already approved this Polivy combination for the treatment of
More from news
Approximately 0 fully matching, plus 359 partially matching documents found.
A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against ... The combination drug was first included in Chinese
Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin
No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL. ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.
The acquisition of Almirall's respiratory business enhances AZ's respiratory franchise bringing a portfolio of marketed and developmental single and combination products for the treatment of asthma and COPD. ... tremelimumab. Existing partners
And again, matching drugs that work well together will be crucial going forward: “Combination treatment will be a critical component; how best to put these drugs together with other checkpoint inhibitors, ... This includes people with NSCLC who have a
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
approval in combination with CyBorD for the treatment of newly diagnosed adult patients with AL amyloidosis. ... Prior to the approval of a new combination treatment for use across Europe, we conducted the first wave of our research to generate a
body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed
The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
No results were found
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...